Pharmaceutics (May 2022)

Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions

  • Damiana Scuteri,
  • Laura Rombolà,
  • Michele Crudo,
  • Chizuko Watanabe,
  • Hirokazu Mizoguchi,
  • Shinobu Sakurada,
  • Kengo Hamamura,
  • Tsukasa Sakurada,
  • Luigi Antonio Morrone,
  • Paolo Tonin,
  • Giacinto Bagetta,
  • Maria Tiziana Corasaniti

DOI
https://doi.org/10.3390/pharmaceutics14051006
Journal volume & issue
Vol. 14, no. 5
p. 1006

Abstract

Read online

The essential oil of bergamot (BEO) has consistently proven antinociceptive and antiallodynic properties. Accordingly, the analgesic efficacy of the decolored essential oil (DEC), with higher levels of limonene, and the deterpenated (DET) fraction, with higher levels of linalool and linalyl acetate, was investigated using a formalin test after inhalation. The present study was aimed at characterizing the effects of BEO, its components with the highest pharmacological activity (represented by linalool, limonene, and linalyl acetate), and its DEC and DET fractions on the formalin test after transdermal administration relevant to clinical translation through topical application. To this aim, the schedule of intervention involved administration immediately after formalin injection or as a 5 min pretreatment followed by washout in ddY-strain mice. This study demonstrates, for the first time, the significant analgesic effect of all three constituents in the first and second phases, accounting for the efficacy of the essential oil in the formalin test. While all fractions revealed equal activity toward the phytocomplex in the early phase, the reduction in time of licking/biting during the late phase was more markedly induced by DEC. Moreover, pretreatment with BEO and its fractions followed by washout did not produce a significant reduction in licking/biting time in both phases of formalin-induced nociceptive response.

Keywords